RCE recce pharmaceuticals ltd

3.33%

31.0¢

Ann: RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program, page-93

First 93 Last

Share
Profile

Follow
Bpharma

4,135 Posts.

497

09/07/20

20:05

Post #: 45762245
Share

Originally posted by GaiusMarius: ↑

I get you argument, but I think RCE are taking the wrong approach, let me explain.

The only reference to antiviral effects I can find is the study in mice with influenza A. At a dose of 500mg/kg there was not significant effect. At 1000mg/kg the viral load was eliminated. For a 70 kg adult, we are talking of a dose of 70 grams. A hefty dose.

My main complaint with RCE is they have a product that could develop into a new antibiotic and ultimately a new group of antibiotics. The anti bacterial market is bigger than the ant viral market. There has not been a new group of antibiotics for more than 20 years. Why are they diverting attention away from the main game. The last quarterly showed they only had cash of $4 Million, burning one million a month. Do they have so many staff they can divert money and time away from that research searching for the holy grail of Covid-19.

Three months ago they announced phase one trial of RECCE 327. Not a dose ha been given. The trial has not started. Why not raise money to finance the trial.

I feel this is a stunt to raise the share price so they can raise capital through a placement and SPP. The last thing biotechnology companies need is a reputation for stunts.

Expand

you are so far behind
first cash wrong
second refer 2016 paper on application of recce in beagles on virus supression
dy own research dont quiz from ill informed and vacant reading

RCE Price at posting: $1.05 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

AII

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

First 93 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 31.0¢		Change 0.010(3.33%)		Mkt cap ! $89.39M

Open	High	Low	Value	Volume
31.0¢	32.0¢	30.0¢	$25.76K	82.29K

Buyers (Bids)

No.	Vol.	Price($)
2	13550	30.0¢

Sellers (Offers)

Price($)	Vol.	No.
31.0¢	18938	1

View Market Depth

No.	Vol.	Price($)
2	13550	0.300
2	34803	0.295
2	50000	0.290
4	131061	0.285
10	251389	0.280

Price($)	Vol.	No.
0.310	18938	1
0.320	5000	1
0.325	12600	1
0.330	114230	1
0.350	51319	4

Last trade - 16.10pm 27/06/2025 (20 minute delay)

RCE (ASX) Chart

Ann: RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program, page-93

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Monash IVF shares cater 25% – Disaster or deep-value play?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program, page-93

Top Stories

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Monash IVF shares cater 25% – Disaster or deep-value play?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News